Cat's Claw for Rheumatoid Arthritis

Rheumatoid arthritis is the highest-quality clinical evidence base for Cat's Claw in any indication. The Mur 2002 randomized double-blind placebo-controlled trial of pentacyclic-alkaloid-standardized Uncaria tomentosa extract added to background disease-modifying anti-rheumatic drug (DMARD) therapy (sulfasalazine or hydroxychloroquine) in 40 rheumatoid arthritis (RA) patients showed a 53.2% fall in the number of painful joints against a 24.1% fall on placebo at week 24 (p = 0.044); the authors called it a modest benefit to the tender joint count. The Piscoya 2001 trial of freeze-dried Uncaria guianensis in osteoarthritis of the knee showed less knee pain during activity (not at rest or at night) over four weeks. The proposed mechanism, drawn from cell studies, is upstream nuclear factor kappa-B (NF-kB) inhibition with downstream tumor necrosis factor-alpha suppression — the same pathway targeted by methotrexate, sulfasalazine, and biologics like adalimumab, but reached pharmacologically rather than through immune-cell-targeting drugs. The only rheumatoid arthritis trial tested Cat's Claw as an add-on to conventional disease-modifying therapy, not as a substitute for it. Untreated rheumatoid arthritis destroys joint architecture in the first two years — the window during which DMARDs and biologics produce the largest long-term outcome benefit. In that trial, Cat's Claw added on top lowered the painful-joint count; using it in place of methotrexate leaves the disease untreated during the window when joint damage builds up.


Table of Contents

  1. Rheumatoid Arthritis — What Cat's Claw Is and Isn't For
  2. The Mur 2002 24-Week Randomized Controlled Trial in Detail
  3. The Piscoya 2001 Osteoarthritis Trial
  4. The NF-kB / Tumor Necrosis Factor-alpha Mechanism
  5. Cat's Claw vs DMARDs (Methotrexate, Sulfasalazine, Hydroxychloroquine)
  6. Cat's Claw vs Biologics (Tumor Necrosis Factor Inhibitors, Interleukin-6 Inhibitors)
  7. Cat's Claw vs Nonsteroidal Anti-Inflammatory Drugs and Steroids
  8. Why Chemotype Determines Whether the Trial Reproduces
  9. How the Mur Trial Was Run
  10. Cautions and Who the Research Raises Concerns For
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Rheumatoid Arthritis — What Cat's Claw Is and Isn't For

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system attacks the synovial lining of joints, producing chronic inflammation, pain, swelling, eventual cartilage destruction, bone erosion, and joint deformity. It typically presents symmetrically in the small joints of the hands and feet, often progressing to involve wrists, elbows, knees, shoulders, and cervical spine. Disease activity is measured clinically (tender joint count, swollen joint count, patient global assessment), serologically (rheumatoid factor, anti-cyclic citrullinated peptide (anti-CCP) antibodies, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)), and increasingly by joint imaging (ultrasound or magnetic resonance imaging (MRI) showing synovitis or erosions).

The most consequential clinical fact about rheumatoid arthritis is the "window of opportunity" concept: the first one to two years after symptom onset is the period during which joint architecture can be preserved if disease-modifying therapy is initiated promptly. Once cartilage is destroyed and bony erosions appear on imaging, they do not heal even if subsequent inflammation is controlled. Modern rheumatology therefore aggressively initiates conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs — methotrexate first-line, sulfasalazine or hydroxychloroquine as alternatives or adjuncts) within weeks to months of diagnosis, with escalation to biologic DMARDs (tumor necrosis factor (TNF) inhibitors, interleukin-6 (IL-6) inhibitors, Janus kinase (JAK) inhibitors, anti-CD20) if disease remains active.

This is the context for Cat's Claw. Cat's Claw is an adjunctive symptom-control and inflammation-reduction agent, used on top of conventional DMARD therapy. It is not a disease-modifying agent in the sense that methotrexate is — there is no evidence it prevents radiographic joint erosion or alters long-term disability outcomes. Patients who choose Cat's Claw instead of DMARDs in the early-disease window risk permanent joint destruction during the years they spend with uncontrolled inflammation.

The role the Mur trial tested was as an add-on to a stable DMARD regimen (sulfasalazine or hydroxychloroquine) in patients with active rheumatoid arthritis. In that role, the authors reported relative safety and a modest benefit to the tender joint count.

Back to Table of Contents

The Mur 2002 24-Week Randomized Controlled Trial in Detail

The Mur, Hartig, Eibl, and Schirmer trial published in the Journal of Rheumatology in 2002 is the foundational clinical evidence for Cat's Claw in rheumatoid arthritis. The trial was conducted at the Department of Internal Medicine, University of Innsbruck, Austria.

Design. Randomized, double-blind, placebo-controlled, 24-week parallel-arm trial. 40 patients with active rheumatoid arthritis who had been on stable background DMARD therapy (sulfasalazine or hydroxychloroquine) for at least six months. Randomization was 1:1 to Cat's Claw extract or matching placebo.

Intervention. The active extract was a pentacyclic-alkaloid-chemotype standardized preparation of Uncaria tomentosa bark, dosed at 60 mg of the standardized extract per day for the first 24 weeks. The extract was selected and verified to contain pentacyclic oxindole alkaloids (POA) with negligible tetracyclic oxindole alkaloid (TOA) contamination — the critical chemotype distinction that determines whether Cat's Claw immune modulation occurs at all (see Immune Modulation deep-dive).

Background therapy. All patients continued their existing DMARD therapy and were permitted stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose oral prednisone (under 10 mg/day) throughout the trial. Dose changes were not permitted during the study period.

Outcome measures. Primary outcomes were number of painful joints and number of swollen joints. Secondary outcomes included Ritchie articular index, duration of morning stiffness, patient and physician global assessments, and laboratory inflammation markers (erythrocyte sedimentation rate, C-reactive protein).

Results at 24 weeks.

Phase 2 (weeks 24–52, open-label extension). After week 24, all patients in the trial — both original Cat's Claw recipients and original placebo recipients — received open-label Cat's Claw extract for an additional 28 weeks. The original Cat's Claw group maintained their improvement. The original placebo group, whose painful-joint count had fallen 24.1% on placebo, showed significant reductions in painful joints (p = 0.003), swollen joints (p = 0.007) and the Ritchie Index (p = 0.004) during the open-label phase compared with their values after 24 weeks of placebo, providing within-subject support for the Cat's Claw effect.

Limitations to note. The trial was small (40 patients) and the dose (60 mg/day standardized extract) is low compared to many retail Cat's Claw products. The selected DMARDs (sulfasalazine, hydroxychloroquine) are weaker DMARDs than methotrexate, which is the modern first-line choice — results may differ in a methotrexate-background population. The trial did not include radiographic outcomes, so the question of whether Cat's Claw modifies joint structural progression remains unanswered. Replication in a larger trial with methotrexate background, including imaging endpoints, would strengthen the evidence substantially but has not been done in the 20+ years since publication.

Back to Table of Contents

The Piscoya 2001 Osteoarthritis Trial

The Piscoya, Rodriguez, Bustamante et al. trial published in Inflammation Research in 2001 examined freeze-dried Uncaria guianensis (the related species, not U. tomentosa) in osteoarthritis of the knee. The choice of species matters: U. guianensis has its own anti-inflammatory profile that overlaps with but is not identical to U. tomentosa.

Design. Randomized, double-blind, placebo-controlled, 4-week trial. 45 patients with osteoarthritis of the knee diagnosed by clinical and radiographic criteria. Randomization was 2:1 to active extract or placebo.

Intervention. Freeze-dried Uncaria guianensis bark, 100 mg/day for 4 weeks.

Results.

Laboratory work in the same study tested the extract on tumor necrosis factor-alpha and prostaglandin E2 production in a mouse macrophage cell line (RAW 264.7 cells), not in the patients. The extract suppressed tumor necrosis factor-alpha production at very low concentrations; it had no effect on basal prostaglandin E2 production but reduced stimulated prostaglandin E2 release (P < 0.05), only at higher concentrations than those needed for tumor necrosis factor-alpha inhibition. The authors concluded its anti-inflammatory properties may come from its ability to inhibit tumor necrosis factor-alpha and, to a lesser extent, prostaglandin E2 production — a pattern pointing mainly to cytokine modulation rather than the prostaglandin blockade of nonsteroidal anti-inflammatory drugs (NSAIDs).

The Piscoya trial is shorter and smaller than the Mur trial, and used U. guianensis rather than U. tomentosa, so the two studies are not directly comparable. But the directionality is consistent with the broader Cat's Claw inflammation-modulating story.

Back to Table of Contents

The NF-kB / Tumor Necrosis Factor-alpha Mechanism

The mechanistic story behind Cat's Claw in arthritis is straightforward and well-mapped to the modern understanding of rheumatoid arthritis pathogenesis. NF-kB is a transcription factor complex that sits inactive in the cytoplasm of resting cells, sequestered by its inhibitor protein IkB. When activating signals reach the cell (tumor necrosis factor-alpha binding to tumor necrosis factor receptor 1 (TNFR1), interleukin-1 (IL-1) binding to the IL-1 receptor, bacterial lipopolysaccharide binding to toll-like receptor 4 (TLR4), and many others), the IkB inhibitor is phosphorylated and degraded, releasing NF-kB to translocate into the nucleus and bind to specific DNA sequences (NF-kB response elements) in the promoter regions of inflammatory target genes.

The downstream gene products driven by NF-kB activation include:

In rheumatoid arthritis, persistent NF-kB activation in synovial macrophages, fibroblast-like synoviocytes, and infiltrating T cells is the molecular engine of chronic joint inflammation. The tumor necrosis factor-alpha output sustains the inflammatory loop, the matrix metalloproteinases destroy cartilage, and the anti-apoptotic gene products prevent the inflammatory cells from dying off on schedule.

In mouse macrophage cells (RAW 264.7), a cat's claw bark extract (a water decoction) cut tumor necrosis factor-alpha production by approximately 65–85% (Sandoval 2000), and the authors called it “a remarkably potent inhibitor of TNFalpha production”; a 1998 study by the same group (Sandoval-Chacón) found a bark extract blocked NF-kB activation in the same cells. In cell studies, the proposed downstream consequence is reduced tumor necrosis factor-alpha output, reduced interleukin-1 and interleukin-6, reduced adhesion molecule expression, reduced matrix metalloproteinase, and reduced anti-apoptotic gene expression — the entire inflammatory cascade is dampened simultaneously rather than blocked at any single downstream effector.

What is not yet known: a 2024 systematic review and meta-analysis of 24 animal studies pooled the effect of cat's claw extracts on inflammation markers. The extracts lowered NF-kB (standardized mean difference -1.19) and interleukin-6 (standardized mean difference -0.72), but did not significantly change tumor necrosis factor-alpha (standardized mean difference 0.18, p = 0.41), interleukin-1 or interleukin-10. So the tumor necrosis factor-alpha suppression seen in cell culture was not confirmed in the pooled animal data. The reviewers found these activities were not tied to one specific class of compounds.

This pleiotropic mechanism is one reason Cat's Claw produces clinical effects across multiple inflammatory conditions (rheumatoid arthritis, osteoarthritis, Crohn's-style colitis) at the same dose. It is also why head-to-head comparison with single-mechanism drugs (a tumor necrosis factor inhibitor, a cyclooxygenase-2 inhibitor) tends to favor the targeted drug at the level of any single cytokine endpoint while Cat's Claw produces broader, milder modulation across the full inflammatory cascade.

Back to Table of Contents

Cat's Claw vs DMARDs (Methotrexate, Sulfasalazine, Hydroxychloroquine)

This is the most important comparison for any rheumatoid arthritis patient considering Cat's Claw.

The bottom line from the evidence: the only trial (Mur 2002) tested Cat's Claw as an add-on to sulfasalazine or hydroxychloroquine, not as a substitute for DMARD therapy. Whether it can lower the nonsteroidal anti-inflammatory drug or low-dose steroid dose people need has not been tested.

Current treatment guidelines. The 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis covers conventional synthetic, biologic and targeted synthetic DMARDs, glucocorticoids, and DMARD use in high-risk groups. It contains 44 recommendations (7 strong and 37 conditional), rated with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, and states that its recommendations “are not prescriptive” and that treatment decisions are made jointly with patients. The 2022 update of the EULAR (European Alliance of Associations for Rheumatology) recommendations sets out 5 overarching principles and 11 recommendations: methotrexate plus glucocorticoids first, and, if the response is insufficient within 3–6 months, a next step chosen by risk factors, adding a biologic or targeted synthetic DMARD. Both guidelines address DMARDs and glucocorticoids; herbal products such as Cat's Claw are not among the treatments their abstracts list. These replace the 2015 American College of Rheumatology guideline and the 2019 EULAR update.

Back to Table of Contents

Cat's Claw vs Biologics (Tumor Necrosis Factor Inhibitors, Interleukin-6 Inhibitors)

Biologic DMARDs are large-molecule drugs that directly target specific cytokines or immune-cell surface markers. The major classes used in rheumatoid arthritis include tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), interleukin-6 inhibitors (tocilizumab, sarilumab), interleukin-1 inhibitors (anakinra), anti-CD20 (rituximab), and anti-CD80/86 (abatacept). Biologics are typically reserved for patients with active disease despite csDMARD therapy. They are highly effective but expensive (often $20,000–$60,000/year retail in the US) and carry serious infection risk because they directly suppress key immune defenses.

Cat's Claw and biologics have mechanistic overlap — both reduce tumor necrosis factor-alpha activity — but operate at different levels and at vastly different magnitudes. A tumor necrosis factor inhibitor like adalimumab can bind and neutralize circulating tumor necrosis factor-alpha to near-zero levels; Cat's Claw modestly reduces tumor necrosis factor-alpha production via upstream NF-kB inhibition. The magnitudes are not comparable.

Combining Cat's Claw with biologics raises particular concerns. The theoretical concerns include:

No trial has tested Cat's Claw in people taking biologics; the clinical data to support combination use are essentially absent.

Back to Table of Contents

Cat's Claw vs Nonsteroidal Anti-Inflammatory Drugs and Steroids

Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac, meloxicam, celecoxib) are the symptomatic mainstay of arthritis pain control. They work through COX inhibition, blocking the conversion of arachidonic acid to inflammatory prostaglandins. They are effective for pain but do not modify disease progression in rheumatoid arthritis. Chronic nonsteroidal anti-inflammatory drug use carries documented risks of gastric ulceration, kidney injury (especially in patients with reduced baseline kidney function or dehydration), and cardiovascular events (the cyclooxygenase-2 cardiovascular signal generalizes partially to non-selective nonsteroidal anti-inflammatory drugs).

Cat's Claw is thought to act upstream of the cyclooxygenase (COX) pathway. In the Piscoya osteoarthritis trial, Cat's Claw reduced pain during activity in patients; in the same study's cell-culture tests (mouse macrophage cells), the extract inhibited tumor necrosis factor-alpha at low concentrations and reduced stimulated prostaglandin E2 release only at higher concentrations — the authors concluded its action may come from inhibiting tumor necrosis factor-alpha and, to a lesser extent, prostaglandin E2. This is mechanistically attractive because it offers an anti-inflammatory effect with a different side-effect profile than nonsteroidal anti-inflammatory drugs.

The proposed use case: people with rheumatoid arthritis on conventional DMARD therapy who take nonsteroidal anti-inflammatory drugs long-term for symptoms. The Mur trial kept nonsteroidal anti-inflammatory drug doses stable, so whether adding Cat's Claw lets people lower that dose has not been tested. The people who carry the most nonsteroidal anti-inflammatory drug risk are older adults and those with reduced kidney function, a history of gastric ulcer, or anticoagulant use; when doses of these drugs are changed, disease activity is usually assessed before and after the change.

Low-dose oral prednisone (under 10 mg/day) is used in some rheumatoid arthritis patients as a bridge therapy while DMARDs reach full effect or in patients with breakthrough disease activity. Long-term low-dose steroids carry documented risks of osteoporosis, glucose intolerance, weight gain, skin thinning, and adrenal suppression. The Mur trial allowed continuation of stable low-dose prednisone, and Cat's Claw demonstrated benefit on top of that background. Whether Cat's Claw can substitute for low-dose steroids in well-controlled disease has not been specifically studied.

Back to Table of Contents

Why Chemotype Determines Whether the Trial Reproduces

The Mur trial used a pentacyclic-alkaloid-standardized extract from a single batch with verified TOA contamination below 0.5%. The clinical effect observed in that trial cannot be expected from a TOA-contaminated bark powder, and the apparent failure of some rheumatoid arthritis patients to respond to retail "Cat's Claw" capsules may be a chemotype-quality problem rather than a real lack of effect.

This is the same chemotype story discussed at length in the Immune Modulation deep-dive and in the Benefits hub overview: 1% TOA contamination reduces POA immune activity by ~30%, and 10% TOA can reduce it by 70%+. Wild-harvested bark is a coin-flip on chemotype. Only laboratory-certified POA-standardized or TOA-free products can be expected to reproduce the Mur trial result.

Commercial cat's claw extracts fall into a few types: pentacyclic-oxindole-alkaloid-standardized extracts (the type used in the Mur trial), water extracts standardized on the water-soluble fraction rather than alkaloid content, and TOA-free extracts (one of which is used in a practitioner-designed Lyme protocol). Products whose label states POA standardization or TOA-free certification can list alkaloid percentages in a certificate of analysis. A bottle that lists only "Cat's Claw bark 500 mg" with no chemotype data has an unknown chemotype and therefore unknown clinical activity.

Back to Table of Contents

How the Mur Trial Was Run

The Mur trial is the one randomized trial of Cat's Claw in rheumatoid arthritis. This is what it did, as reported:

For rheumatoid arthritis patients on biologics (adalimumab, etanercept, infliximab, tocilizumab, etc.), the combination with Cat's Claw has not been studied; the concerns are theoretical — additive infection risk and unknown pharmacokinetic and pharmacodynamic effects (how the body handles each drug and how the two act together).

Back to Table of Contents

Cautions and Who the Research Raises Concerns For

For the broader anti-inflammatory and gastrointestinal applications and additional safety detail, see the anti-inflammatory deep-dive.

Back to Table of Contents

Key Research Papers

  1. Mur E, Hartig F, Eibl G, Schirmer M (2002). Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. Journal of Rheumatology 29(4): 678–681. — PubMed PMID: 11950006
  2. Piscoya J, Rodriguez Z, Bustamante SA, et al. (2001). Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflammation Research 50(9): 442–448. — PubMed PMID: 11603848
  3. Sandoval-Chacón M, Thompson JH, Zhang XJ, et al. (1998). Antiinflammatory actions of cat's claw: the role of NF-kappaB. Alimentary Pharmacology & Therapeutics 12(12): 1279–1289. — PubMed PMID: 9882039
  4. Sandoval M, Charbonnet RM, Okuhama NN, et al. (2000). Cat's claw inhibits TNF-alpha production and scavenges free radicals: role in cytoprotection. Free Radical Biology and Medicine 29(1): 71–78. — PubMed PMID: 10962207
  5. Sandoval M, Okuhama NN, Zhang XJ, et al. (2002). Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 9(4): 325–337. — PubMed PMID: 12120814
  6. Aguilar JL, Rojas P, Marcelo A, et al. (2002). Anti-inflammatory activity of two different extracts of Uncaria tomentosa (Rubiaceae). Journal of Ethnopharmacology 81(2): 271–276. — PubMed PMID: 12065162
  7. Keplinger K, Laus G, Wurm M, Dierich MP, Teppner H (1999). Uncaria tomentosa (Willd.) DC. — ethnomedicinal use and new pharmacological, toxicological and botanical results. Journal of Ethnopharmacology 64(1): 23–34. — PubMed PMID: 10075119 (Editorial note: the review reports that tetracyclic oxindole alkaloids act as antagonists of the pentacyclic oxindole alkaloids.)
  8. Allen-Hall L, Cano P, Arnason JT, et al. (2007). Treatment of THP-1 cells with Uncaria tomentosa extracts differentially regulates the expression of IL-1beta and TNF-alpha. Journal of Ethnopharmacology 109(2): 312–317. — PubMed PMID: 16959454
  9. Hardin SR (2007). Cat's claw: an Amazonian vine decreases inflammation in osteoarthritis. Complementary Therapies in Clinical Practice 13(1): 25–28. — PubMed PMID: 17210508
  10. Arado GM, Amatto PPG, Marins M, et al. (2024). Anti-inflammatory and/or immunomodulatory activities of Uncaria tomentosa (cat's claw) extracts: a systematic review and meta-analysis of in vivo studies. Frontiers in Pharmacology 15: 1378408. — PubMed PMID: 38881881
  11. Hilepo JN, Bellucci AG, Mossey RT (1997). Acute renal failure caused by 'cat's claw' herbal remedy in a patient with systemic lupus erythematosus. Nephron 77(3): 361. — PubMed PMID: 9375835
  12. López Galera RM, Ribera Pascuet E, Esteban Mur JI, Montoro Ronsano JB, Juárez Giménez JC (2008). Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir. European Journal of Clinical Pharmacology 64(12): 1235–1236. — PubMed PMID: 18712519
  13. Fraenkel L, Bathon JM, England BR, et al. (2021). 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology 73(7): 1108–1123. — PubMed PMID: 34101376
  14. Smolen JS, Landewé RBM, Bergstra SA, et al. (2023). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases 82(1): 3–18. — PubMed PMID: 36357155
  15. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 79(6): 685–699. — PubMed PMID: 31969328 (Earlier edition, superseded by the 2022 update above.)
  16. Singh JA, Saag KG, Bridges SL Jr, et al. (2016). 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology 68(1): 1–26. — PubMed PMID: 26545940 (Earlier edition, superseded by the 2021 guideline above.)
  17. Setty AR, Sigal LH (2005). Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Seminars in Arthritis and Rheumatism 34(6): 773–784. — PubMed PMID: 15942912

PubMed Topic Searches

  1. PubMed: Uncaria tomentosa rheumatoid arthritis
  2. PubMed: Uncaria tomentosa osteoarthritis
  3. PubMed: Cat's Claw TNF-alpha and inflammation
  4. PubMed: Herbal adjuncts to methotrexate in RA
  5. PubMed: Plant-derived NF-kB inhibitors in arthritis

Back to Table of Contents

Connections

Back to Table of Contents